SARS-CoV-2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease.
SARS-CoV-2 vaccination
autoimmune hepatitis
chronic liver disease
immunosuppression
primary biliary cholangitis
primary sclerosing cholangitis
Journal
United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
18
11
2021
accepted:
13
02
2022
pubmed:
16
3
2022
medline:
14
4
2022
entrez:
15
3
2022
Statut:
ppublish
Résumé
In this observational study, we explored the humoral and cellular immune response to SARS-CoV-2 vaccination in patients with autoimmune hepatitis (AIH) and patients with cholestatic autoimmune liver disease (primary sclerosing cholangitis [PSC] and primary biliary cholangitis [PBC]). Anti-SARS-CoV-2 antibody titers were determined using the DiaSorin LIAISON and Roche immunoassays in 103 AIH, 64 PSC, and 61 PBC patients and 95 healthy controls >14 days after the second COVID-19 vaccination. The spike-specific T-cell response was assessed using an activation-induced marker assay (AIM) in a subset of individuals. Previous SARS-CoV-2 infection was frequently detected in AIH but not in PBC/PSC (10/112 (9%), versus 4/144 (2.7%), p = 0.03). In the remaining patients, seroconversion was measurable in 97% of AIH and 99% of PBC/PSC patients, respectively. However, in 13/94 AIH patients antibody levels were lower than in any healthy control, which contributed to lower antibody levels of the total AIH cohort when compared to PBC/PSC or controls (641 vs. 1020 vs. 1200 BAU/ml, respectively). Notably, antibody levels were comparably low in AIH patients with (n = 85) and without immunosuppression (n = 9). Also, antibody titers significantly declined within 7 months after the second vaccination. In the AIM assay of 20 AIH patients, a spike-specific T-cell response was undetectable in 45% despite a positive serology, while 87% (13/15) of the PBC/PSC demonstrated a spike-specific T-cell response. Patients with AIH show an increased SARS-CoV-2 infection rate as well as an impaired B- and T-cell response to SARS-CoV-2 vaccine compared to PBC and PSC patients, even in the absence of immunosuppression. Thus, antibody responses to vaccination in AIH patients need to be monitored and early booster immunizations considered in low responders.
Sections du résumé
BACKGROUND/AIMS
In this observational study, we explored the humoral and cellular immune response to SARS-CoV-2 vaccination in patients with autoimmune hepatitis (AIH) and patients with cholestatic autoimmune liver disease (primary sclerosing cholangitis [PSC] and primary biliary cholangitis [PBC]).
METHODS
Anti-SARS-CoV-2 antibody titers were determined using the DiaSorin LIAISON and Roche immunoassays in 103 AIH, 64 PSC, and 61 PBC patients and 95 healthy controls >14 days after the second COVID-19 vaccination. The spike-specific T-cell response was assessed using an activation-induced marker assay (AIM) in a subset of individuals.
RESULTS
Previous SARS-CoV-2 infection was frequently detected in AIH but not in PBC/PSC (10/112 (9%), versus 4/144 (2.7%), p = 0.03). In the remaining patients, seroconversion was measurable in 97% of AIH and 99% of PBC/PSC patients, respectively. However, in 13/94 AIH patients antibody levels were lower than in any healthy control, which contributed to lower antibody levels of the total AIH cohort when compared to PBC/PSC or controls (641 vs. 1020 vs. 1200 BAU/ml, respectively). Notably, antibody levels were comparably low in AIH patients with (n = 85) and without immunosuppression (n = 9). Also, antibody titers significantly declined within 7 months after the second vaccination. In the AIM assay of 20 AIH patients, a spike-specific T-cell response was undetectable in 45% despite a positive serology, while 87% (13/15) of the PBC/PSC demonstrated a spike-specific T-cell response.
CONCLUSION
Patients with AIH show an increased SARS-CoV-2 infection rate as well as an impaired B- and T-cell response to SARS-CoV-2 vaccine compared to PBC and PSC patients, even in the absence of immunosuppression. Thus, antibody responses to vaccination in AIH patients need to be monitored and early booster immunizations considered in low responders.
Identifiants
pubmed: 35289983
doi: 10.1002/ueg2.12218
pmc: PMC9004241
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
319-329Informations de copyright
© 2022 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.
Références
Clin Gastroenterol Hepatol. 2022 Jan;20(1):162-172.e9
pubmed: 34509643
J Clin Microbiol. 2021 Jan 21;59(2):
pubmed: 33139419
Lancet Reg Health Eur. 2021 Oct;9:100178
pubmed: 34318288
Ann Intern Med. 2021 Nov;174(11):1572-1585
pubmed: 34461029
N Engl J Med. 2021 Sep 23;385(13):1244-1246
pubmed: 34379917
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Rheumatol Int. 2020 Sep;40(9):1353-1360
pubmed: 32654078
J Hepatol. 2015 Mar;62(3):642-6
pubmed: 25457202
Front Immunol. 2021 Sep 30;12:708848
pubmed: 34659200
Int J Hyg Environ Health. 2021 Sep;238:113851
pubmed: 34601375
United European Gastroenterol J. 2022 Apr;10(3):319-329
pubmed: 35289983
Hepatology. 1995 Aug;22(2):381-8
pubmed: 7635404
Liver Transpl. 2020 Jul;26(7):866-877
pubmed: 32112516
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
Infect Dis Ther. 2021 Dec;10(4):2381-2397
pubmed: 34368915
J Clin Virol. 2021 Jun;139:104820
pubmed: 33865031
J Hepatol. 2021 Jun;74(6):1335-1343
pubmed: 33508378
Clin Chem Lab Med. 2021 Mar 15;59(8):1463-1467
pubmed: 33711225
N Engl J Med. 2021 Jun 10;384(23):2259-2261
pubmed: 33822494
Front Immunol. 2021 Jul 27;12:734689
pubmed: 34386018
J Hepatol. 2021 Dec;75(6):1434-1439
pubmed: 34454993
Gut. 2021 Oct;70(10):1884-1893
pubmed: 33903149
J Hepatol. 2021 Aug;75(2):435-438
pubmed: 33892006